Optimizing Biologically Targeted Clinical Trials for Neurofibromatosis

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1517/13543784.2013.772979
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare